佐力藥業(300181.SZ):擬1065.68萬元向實控人之子收購拓普藥業8%股權
格隆匯12月28日丨佐力藥業(300181.SZ)公佈,為進一步完善公司上下游產業鏈、發揮業務協同效應,有效應對市場變化,公司擬以1065.68萬元人民幣通過協議轉讓的方式收購浙江拓普藥業股份有限公司(簡稱“拓普藥業”)股東俞寅持有拓普藥業8%的股權。該次交易完成後,拓普藥業將成為公司參股公司。俞寅系公司控股股東、實際控制人俞有強之子,為公司關聯方。
公司近期獲批的聚卡波非鈣片用於緩解腸易激綜合徵(便祕型)患者的便祕症狀(後期公司將圍繞增加用於腹瀉適應症進行二次開發),系《國家醫保目錄》(2021年版)品種,在美國、歐洲及日本得到廣泛應用。該品種的獲批進一步豐富了公司的品種線,其與烏靈膠囊在消化科的應用有一定的協同效應,為公司重點培育的新品種。
拓普藥業為公司聚卡波非鈣片原料藥聚卡波非鈣的唯一供應商,拓普藥業屬於特色原料藥和醫藥中間體行業,主要從事醫藥中間體、原料藥的研發、生產與銷售,擁有獨立完整的採購、生產和銷售體系,拓普藥業生產的原料藥聚卡波非鈣達到國際標準。
該次交易系公司經營發展需要,有利於增加聚卡波非鈣原料供應的穩定性,完善公司上下游產業鏈、充分發揮業務協同效應,有效應對市場變化,從而提升公司整體競爭優勢。同時,公司將根據聚卡波非鈣片的市場開拓、拓普藥業的經營發展等情況決定後續增持拓普藥業股份事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.